Linezolid is a new antibiotic against HRSA infection and has a broad market prospect.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Linezolid Impurity LNZA-E is a critical synthetic intermediate and degradation product associated with the oxazolidinone antibiotic Linezolid. It serves as a reference standard for quality control in pharmaceutical manufacturing to ensure purity compliance. <strong>Molecular Formula</strong>: C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>. <strong>CAS No.</strong>: 176097-66-2.</p>
<h3>Application</h3>
<ul>
<li>Pharmaceutical R&D for method development and validation of analytical procedures.</li>
<li>Quality Control laboratories for establishing impurity profiles during stability testing.</li>
<li>Regulatory submissions to demonstrate compliance with ICH Q3A/B guidelines.</li>
</ul>
<h3>Precautions</h3>
<p>Store in a cool, dry place protected from light at temperatures below -20°C. Handle only in well-ventilated areas using appropriate PPE due to potential irritant properties. Do not use as a therapeutic agent; strictly for laboratory research and reference purposes only.</p>